News | Atrial Fibrillation | May 26, 2023

New Device Helps Prevent Complication During Common Heart Procedure

By gently diverting the esophagus, heart ablations will be safer

Emile Daoud, MD, helped develop a new surgical device at The Ohio State University Wexner Medical Center to prevent a common and serious complication during heart ablation procedures. The device gently moves the nearby esophagus away from the heart to prevent the ablation energy from causing damage.

May 26, 2023 — Atrial fibrillation, or AFib , is the most common heart rhythm problem, affecting millions of Americans and greatly increasing their risk of stroke and heart failure. For some with AFib, a catheter ablation is used to burn or freeze the precise area causing the problem to restore a normal heart rhythm. While this method is effective in treating AFib, the energy from the catheter tip can cause serious damage to the adjacent esophagus, which is only a few millimeters away. It’s an injury that can be life threatening, so an electrophysiologist at The Ohio State University Wexner Medical Center helped develop a new device that gently diverts the esophagus out of harm’s way, greatly improving safety. 

“On one hand, we want to deliver high energy and spend a lot of time ablating a specific spot to get a good, deep lesion. But on the other hand, we are very cognizant of where the esophagus is and want to do everything possible to avoid damaging that structure,” said Emile Daoud, MD, electrophysiologist and clinical professor of internal medicine at the medical center. “By pulling in the esophagus using suction force and then moving the entire segment to the side by about an inch, we are able to create a safe pathway to deliver the energy to treat AFib.”

A clinical trial led by Ohio State found that without the device, over a third of heart ablation patients had esophageal injuries, but when the new device was used, less than 5% of patients had any injury to the esophagus, and they were much less severe than the control group.

“There have been attempts to protect the esophagus during heart ablations in the past using different techniques like measuring the temperature inside the esophagus, using ultrasound imaging to identify where it’s located and using shorter or less intense ablation energy, but esophageal injury continued to be a serious problem,” said Daoud. “With this device, patients can rest assured that they are getting the safest procedure possible without compromising any benefits to their heart.”

For more information: https://health.osu.edu/

Find more HRS23 conference coverage here


Related Content

News | Heart Failure

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care ...

Home October 28, 2025
Home
News | Heart Failure

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association ...

Home October 16, 2025
Home
News | Heart Failure

Sept. 24, 2025 — The Family Heart Foundation, a leading research and advocacy organization, has announced the online ...

Home September 24, 2025
Home
News | Heart Failure

Sept. 22, 2025 — The latest findings on heart failure (HF) published by the Heart Failure Society of America (HFSA) ...

Home September 22, 2025
Home
News | Heart Failure

Sept. 11, 2025 — Newswise — A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women ...

Home September 15, 2025
Home
News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
Subscribe Now